Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Matthew Dankner(McGill University Health Centre), April A. N. Rose(University of Toronto), Shivshankari Rajkumar(McGill University Health Centre), Peter M. Siegel(McGill University Health Centre), Ian R. Watson(McGill University)

Oncogene

March 13, 2018

10.1038/s41388-018-0171-x

Cited by 556

Abstract

Related Papers

Genomic Classification of Cutaneous Melanoma

Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy et al.|Cell|2015|3.2k

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al.|New England Journal of Medicine|2014|2.6k

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

David M. Hyman, Igor Puzanov, Vivek Subbiah et al.|New England Journal of Medicine|2015|1.7k

BrafV600E cooperates with Pten loss to induce metastatic melanoma

David Dankort, David P. Curley, Robert A Cartlidge et al.|Nature Genetics|2009|1.2k

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition

Zhan Yao, Neilawattie M. Torres, Anthony Tao et al.|Cancer Cell|2015|544